Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Pacritinib in KSHV-Associated MCD and KICS
NCT06052618Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2025
- Primary completion
- Jan 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pacritinib in multicentric Castleman disease (MCD), Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS), sponsored by National Cancer Institute. Started Mar 2025; status: recruiting.
02
Drugs
pacritinib
03
Conditions
multicentric Castleman disease (MCD)Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS)
Beyond the preview
Go deeper on NCT06052618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052618.